An Objective, Fully Automated Barrett’s Risk Prediction Assay Outperforms Most Pathologists in Risk Stratifying Barrett’s Esophagus With Low Grade Dysplasia

Aims Low-grade dysplasia (LGD) is the best predictor of malignant progression in Barrett’s Esophagus (BE). LGD is over-diagnosed, therefore guidelines recommend expert histological revision. TissueCypher is an objective, automated BE risk prediction assay, previously validated. We aimed to evaluate the predictive value of TissueCypher in BE patients with community-based LGD and to benchmark its performance against an international panel of pathologists.